TY -的T1 Ocrelizumab对免疫的影响参数在一群女士的病人(p4.2 - 049) JF -神经学乔-神经学六世- 92 - 15补充SP - p4.2 - 049 AU -你们胡盟Laksh首页man Arcot Jayagopal AU -迈克尔Persenaire盟安妮特Wundes AU -格洛丽亚·冯·Geldern Y1 - 2019/04/09 UR - //www.ez-admanager.com/content/92/15_supplement/p4.2 - 049. -抽象N2 -目的:检查Ocrelizumab对血清淋巴细胞亚群和免疫球蛋白的影响在实际settingBackground: Ocrelizumab是最近通过单克隆抗体靶向细胞治疗复发和主要进展型多发性硬化症(MS)。设计/方法:回顾性的图表总结和纵向分析的实验室和临床资料包括血清ocrelizumab患者淋巴细胞亚群和免疫球蛋白在女士在我们中心。结果:分析113例包括:55岁男性,58岁女性,平均年龄45.1岁;73.4%复发汇款和26.6%进步女士之前大多数病人在疾病修饰治疗(85.8%),而14.2%是首次治疗。ocrelizumab第一剂量后,所有患者有显著减少意味着酒精度和CD3(分别为24.4%和11.8%,p & lt;0.0001),意味着CD4 / CD8比率增加13.5%(术中,0.0001)。首次治疗的病人表现出显著的减少意味着酒精度,CD3, CD4, CD8计数(p = 0.02 40.1%, p = 0.03 26.4%, p = 0.02 15.8%, 51.8%, p = 0.03)。病人从natalizumab证明显著减少意味着酒精度和CD4(48.6%,术中;0.0001,25.2%分别p = 0.006)。fingolimod的那些开关显示显著增加意味着CD3, CD4, CD8, CD4/8比率(p = 0.002 51.1%, p = 0.001 48.9%, p = 0.012 25.6%, 45.5%, p = 0.0001)。基线异常免疫球蛋白和IgM水平低8.1%和15.6%的人群。随访12个月,低免疫球蛋白水平被发现在28.9%的患者低19.8%,IgM。总共有38感染但没有机会性感染被报道。没有观察到感染和搞笑状态之间的关系。结论:b细胞耗竭超出了预期,影响t淋巴球子集和免疫球蛋白水平与ocrelizumab MS患者中观察到。 While the clinical significance is undetermined, data may suggest the importance of clinical vigilance in those treated with ocrelizumab.Disclosure: Dr. Hu has nothing to disclose. Dr. Jayagopal has nothing to disclose. Dr. Persenaire has nothing to disclose. Dr. Wundes has received research support from Biogen and Alkermes. Dr. Von Geldern has nothing to disclose. ER -